Next Article in Journal
Genetic Variation and Biological Activity of Two Closely Related Alphabaculoviruses during Serial Passage in Permissive and Semi-Permissive Heterologous Hosts
Next Article in Special Issue
Metagenomic Next-Generation Sequencing Reveal Presence of a Novel Ungulate Bocaparvovirus in Alpacas
Previous Article in Journal
Genome Analysis of A Novel South African Cydia pomonella granulovirus (CpGV-SA) with Resistance-Breaking Potential
Previous Article in Special Issue
Systematic Review of PCR Proof of Parvovirus B19 Genomes in Endomyocardial Biopsies of Patients Presenting with Myocarditis or Dilated Cardiomyopathy
Open AccessReview

Advances in the Development of Antiviral Strategies against Parvovirus B19

Department of Pharmacy and Biotechnology, University of Bologna, I-40138 Bologna, Italy
*
Author to whom correspondence should be addressed.
Viruses 2019, 11(7), 659; https://doi.org/10.3390/v11070659
Received: 25 June 2019 / Revised: 16 July 2019 / Accepted: 17 July 2019 / Published: 18 July 2019
(This article belongs to the Special Issue New Insights into Parvovirus Research)
  |  
PDF [1231 KB, uploaded 22 July 2019]
  |  

Abstract

Parvovirus B19 (B19V) is a human pathogenic virus, responsible for an ample range of clinical manifestations. Infections are usually mild, self-limiting, and controlled by the development of a specific immune response, but in many cases clinical situations can be more complex and require therapy. Presently available treatments are only supportive, symptomatic, or unspecific, such as administration of intravenous immunoglobulins, and often of limited efficacy. The development of antiviral strategies against B19V should be considered of highest relevance for increasing the available options for more specific and effective therapeutic treatments. This field of research has been explored in recent years, registering some achievements as well as interesting future perspectives. In addition to immunoglobulins, some compounds have been shown to possess inhibitory activity against B19V. Hydroxyurea is an antiproliferative drug used in the treatment of sickle-cell disease that also possesses inhibitory activity against B19V. The nucleotide analogues Cidofovir and its lipid conjugate Brincidofovir are broad-range antivirals mostly active against dsDNA viruses, which showed an antiviral activity also against B19V. Newly synthesized coumarin derivatives offer possibilities for the development of molecules with antiviral activity. Identification of some flavonoid molecules, with direct inhibitory activity against the viral non-structural (NS) protein, indicates a possible line of development for direct antiviral agents. Continuing research in the field, leading to better knowledge of the viral lifecycle and a precise understanding of virus–cell interactions, will offer novel opportunities for developing more efficient, targeted antiviral agents, which can be translated into available therapeutic options. View Full-Text
Keywords: parvovirus B19; erythroid progenitor cells; antiviral compounds; intravenous immunoglobulin (IVIG); hydroxyurea; cidofovir; brincidofovir; coumarin derivatives; flavonoids parvovirus B19; erythroid progenitor cells; antiviral compounds; intravenous immunoglobulin (IVIG); hydroxyurea; cidofovir; brincidofovir; coumarin derivatives; flavonoids
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Manaresi, E.; Gallinella, G. Advances in the Development of Antiviral Strategies against Parvovirus B19. Viruses 2019, 11, 659.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top